Memantine Hydrochloride Tablet
Product Images NDC 63629-2512

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 63629-2512). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 01)

Chemical structure of Memantine Hydrochloride showing its molecular framework with attached NH2 and HCl groups and methyl substituents.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 02)

A line graph depicting mean change from baseline in ADCS-ADL score over 28 weeks of treatment comparing Memantine Hydrochloride (M.HCl) and placebo. The y-axis shows mean change with clinical improvement indicated at the top and clinical decline at the bottom. Data points with error bars show less decline over time in the M.HCl group compared to placebo.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 03)

A cumulative percentage of patients plot comparing Placebo and Memantine Hydrochloride (M.HCl) groups. The x-axis shows ADCS-ADL change from baseline, ranging from 10 to -25. The y-axis represents cumulative percentage from 0 to 100%. The graph uses square markers for Placebo and circle markers for M.HCl, illustrating differences in patient responses over the change scores.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 04)

A line graph depicting the mean change from baseline in SIB score over 28 weeks of treatment. The X-axis represents weeks of treatment (0 to 28), and the Y-axis indicates the mean change plus or minus SEM. Two lines compare Placebo and Memantine Hydrochloride (M.HCl) effects, showing clinical improvement and decline trends throughout the study period.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 05)

A cumulative percentage plot showing the change in SIB (Severe Impairment Battery) scores from baseline in patients treated with Memantine Hydrochloride (M. HCl) compared to placebo. The X-axis represents SIB change from baseline, and the Y-axis indicates the cumulative percentage of patients. Two curves are shown: one for placebo and one for Memantine Hydrochloride.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 06)

A line graph showing mean change from baseline in ADCS-ADL scores over 24 weeks of treatment, comparing Placebo/Donepezil and Memantine Hydrochloride/Donepezil groups. The graph indicates clinical improvement and decline thresholds, plotting changes with error bars at multiple time points.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 07)

A cumulative percentage of patients chart depicting ADCS-ADL change from baseline. The graph compares two groups: Placebo/Donepezil and Memantine Hydrochloride (M. HCl)/Donepezil, showing patient response distribution across a range of baseline changes.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 08)

A line graph illustrating mean change from baseline in SIB score over 24 weeks of treatment. Two groups are compared: Placebo/Donepezil (black squares) and Memantine Hydrochloride/Donepezil (open circles). The x-axis represents weeks of treatment; the y-axis shows mean change with clinical improvement indicated above and clinical decline below a zero baseline. Error bars show ± SEM.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 09)

A cumulative percentage of patients chart comparing SIB (Severe Impairment Battery) changes from baseline between two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The x-axis shows SIB change from baseline ranging approximately from +20 to -30, and the y-axis shows the cumulative percentage of patients from 0% to 100%. Two curve lines are shown, one marked with squares (Placebo/Donepezil) and the other with circles (Memantine Hydrochloride/Donepezil).*

FDA Label Image

Label (Lbl636292512)

Label for Memantine Hydrochloride Tablets, USP 10 mg by Bryant Ranch Prepack. The label shows the NDC 63629-2512-1, a barcode, and indicates the product contains 60 tablets for oral use. Storage and dispensing instructions are also displayed, along with the labeler's location in Burbank, CA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.